Biomarin

10 key clinical trials to watch in the first half of 2021
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
Flag link:
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian
Flag link:
10 Biopharma Stories to Look Forward to in 2021
10 Biopharma Stories to Look Forward to in 2021
BioSpace
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
Flag link:
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
Flag link:
Deep Genomics hits the partnering ground running with BioMarin deal
Deep Genomics hits the partnering ground running with BioMarin deal
Fierce Biotech
Deep Genomics
Biomarin
drug discovery
artificial intelligence
Flag link:
How BioMarin Beat Expectations in Q3
How BioMarin Beat Expectations in Q3
Motley Fool
Biomarin
hemophilia A
earnings
Flag link:
BioMarin nabs FDA review for dwarfism drug vosoritide, forgoes AdComm as it eyes 2021 approval
BioMarin nabs FDA review for dwarfism drug vosoritide, forgoes AdComm as it eyes 2021 approval
Fierce Biotech
Biomarin
FDA
vosoritide
dwarfism
Flag link:
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
Yahoo/Zacks.com
Biomarin
FDA
achondroplasia
dwarfism
Flag link:
2 major FDA rejections leave some pharma investors worried about intensification of regulations
2 major FDA rejections leave some pharma investors worried about intensification of regulations
Beckers Hospital Review
FDA
drug approvals
drug development
Gilead Sciences
Biomarin
Flag link:
Is valrox dead?
Is valrox dead?
EP Vantage
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
Flag link:
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
Fierce Biotech
Biomarin
FDA
valrox
hemophilia A
Flag link:
How Biomarin Beat Expectations in Q2
How Biomarin Beat Expectations in Q2
Motley Fool
Biomarin
earnings
Flag link:
Go or no go? Valuable drugs set for FDA decisions
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
Flag link:
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
Flag link:
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
Flag link:
BioMarin gene therapy shows sustained benefit in hemophilia A study
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Flag link:
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Yahoo/PR Newswire
Biomarin
DiNAQOR
gene therapy
cardiomyopathy
Flag link:
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
Motley Fool
Biomarin
earnings
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:

Pages